Intelligence for regulated teams.

Data integrity deficiencies, inadequate validation documentation, and audit trail failures continue to dominate 483 observations. Here is what your team needs to address immediately.

As AI systems penetrate clinical decision support, pharmacovigilance, and drug discovery, the world's first AI management standard is becoming a compliance baseline.

The 2022 Second Edition fundamentally reframes how validation evidence is generated. Risk-based testing and meaningful assurance replace checkbox compliance.

Missing audit trail reviews, shared user accounts, weak password controls, and inadequate electronic signature implementation continue to top FDA's 483 observation list.

Cloud-hosted GxP systems face heightened EMA scrutiny. Supplier qualification, data sovereignty, audit trail accessibility, and disaster recovery documentation.

Learn how to structure severity, probability, and detectability scoring, document mitigation controls, and present residual risk in a way that gives inspectors confidence.